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CASE REPORTTechnetium-99m MIBI uptake at sites of
heterotopic calcification in a patient with chronic
renal failure and a previously resected parathyroid
carcinoma
M. Walsha,*, N.E. Manghata, T. Sulkina, R.G. ParrybDepartments of aClinical Imaging, and bNephrology, Royal Cornwall Hospital, Truro, UKIntroduction
Parathyroid carcinoma is a rare cause of primary
hyperparathyroidism. The primary tumour exhibits
a wide range of malignancy and distant as well as
local recurrence. The use of technetium-99m
methoxy-isobutyl-isonitrile (Tc-99m MIBI, Cardio-
lite, Dupont Pharmaceuticals, Bristol, UK) scinti-
graphy in the localization of parathyroid carcinoma
before surgical resection and in the detection of
metastatic disease is well documented.1–3 We
present a case of increased Tc-99m MIBI uptake at
sites of heterotopic calcification in a 44-year-old
man with end-stage renal failure, with a previously
resected parathyroid carcinoma. To the best of our
knowledge this has not been previously described,
but awareness of this possibility in cases with a
history of parathyroid carcinoma is important in
avoiding an erroneous diagnosis of metastatic
disease.
The radiographic and scintigraphic appearances
are illustrated and the current knowledge regarding
heterotopic calcification in the context of para-
thyroid carcinoma and chronic renal failure is
discussed.Case report
A 44-year-old male engineer with end-stage renal
failure secondary to chronic IgA nephropathy
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ous ambulatory peritoneal dialysis. The biochemi-
cal parameters at this time demonstrated raised
levels of serum corrected calcium (cCa2C),
2.76 mmol/l (normal range 2.2 to 2.6 mmol/l);
inorganic phosphate ðiPO3K4 Þ, 1.48 mmol/l (normal
range 0.8 to 1.4 mmol/l); alkaline phosphatase
(AP), 138 IU/l (normal range 45 to 122 IU/l); and
parathyroid hormone (PTH), 745 pmol/l (normal
range !0.8 to 8.5 pmol/l).
This case was initially managed as secondary
hyperparathyroidism of chronic renal failure, with
carefully titrated pulsed vitamin D to suppress the
PTH level without increasing the serum calcium
level further. Despite this measure, over the
following 2 months the serum PTH and cCa2C levels
increased to 1440 pmol/l and 3.26 mmol/l, respect-
ively. The man developed gynaecomastia and an
increasing right supraclavicular mass, the latter
confirmed as a site of heterotopic calcification on
plain film. The disproportionately high PTH level
raised the suspicion of an underlying parathyroid
adenoma or carcinoma. Neck US showed a 3.2-cm
hypoechoic mass inseparable from the posterior
aspect of the lower pole of the right lobe of the
thyroid. Tc-99m MIBI scinitigraphy demonstrated an
intensely active focus, which correlated with the
location of the lesion demonstrated on US, consist-
ent with a parathyroid adenoma or carcinoma.
Surgical exploration of the neck was undertaken,
and a 3-cm mass was identified posterior to the
right inferior thyroid artery. It was resected with
difficulty because of firm adherence to the oeso-
phagus and trachea; the right-sided supraclavicular
calcific mass was also resected during the pro-
cedure. The remaining parathyroid glands could
not be identified at the time of surgery. HistologyClinical Radiology Extra (2005) 60, 69–74gists. Published by Elsevier Ltd. All rights reserved.
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carcinoma with vascular and capsular invasion,
and involvement of the resection margins was
equivocal. The supraclavicular mass was composed
of crystalline calcified material consistent with
heterotopic calcification, with no evidence of
surrounding granulomatous reaction.
Following surgery, a prompt biochemical
response was observed with a progressive fall in
the serum levels of cCa2C, iPO3K4 , AP and PTH to
within normal limits. This biochemical response was
monitored and sustained for 9 months, at which
point a rise in the PTH level to 200 pmol/l was noted
and the man complained of lumps of increasing size
in the left thumb and elbow (Fig. 1). The lesion inFigure 1 Pictures of the left (a) thumb and (b) elbow, 9
months following resection of a parathyroid carcinoma,
demonstrating superficial masses which were firm on
palpation.the thumb resulted in significant pain and loss of
function. Plain films of the affected joints demon-
strated calcification within the soft tissues of the
distal left thumb and posterolateral aspect of the
left elbow joint (Fig. 2). A whole-body Tc-99m MIBI
scan was performed at this time to exclude local or
distant recurrence of parathyroid carcinoma. The
only abnormal finding was increased tracer uptake
in the distal left thumb, corresponding to the soft-
tissue calcification identified on the plain film, and
a metastasis at this site could not be excluded
(Fig. 3). Surgical debulking of the calcified mass
within the left thumb was performed to improve
joint function and to exclude metastatic disease.
Histology of the resected specimen confirmed large
deposits of calcium with a surrounding granuloma-
tous reaction within dermal collagen, consistent
with heterotopic calcification. There was no
evidence of metastatic disease, so the rising PTH
level was attributed to progressive secondary
hyperparathyroidism.
Medical management at this time consisted of
optimizing peritoneal dialysis, and the adminis-
tration of intravenous vitamin D analogue to
suppress parathyroid hormone levels and oral
phosphate binders to decrease inorganic phosphate
levels. During the following 12 months, the foci of
heterotopic calcification around the thumb and
elbow continued to increase in size and new foci of
soft-tissue calcification developed within the ball of
the right foot and right flank (Fig. 4). CT of the
abdomen demonstrated the right flank calcification
lying within the psoas, iliacus, erector spinae and
pectineus muscles (Fig. 5). Repeat Tc-99m MIBI
imaging (Fig. 6), showed increased activity within
the left thumb and elbow on early- and late-phase
images. The degree of tracer uptake had progressed
when compared with the study performed 16
months earlier. There was no tracer uptake within
the abdominal wall calcification. Serum biochemi-
cal parameters during this period demonstrated a
normal serum cCa2C, persistently raised iPO3K4 of
approximately 1.7 mmol/l and raised PTH levels
ranging between 200 and 600 pmol/l. Although the
clinical suspicion at this time was a recurrence of
parathyroid carcinoma, repeated Tc-99m MIBI
scintigraphy failed to demonstrate increased
uptake within the neck or at sites away from
known deposits of heterotopic calcification; there-
fore, the biochemical picture was managed as
secondary hyperparathyroidism of chronic renal
failure, without evidence of recurrent disease.
The current management of this relentlessly
progressive and disabling calcification remains
difficult. Bisphosphonate infusions were com-
menced and preparations for haemodialysis have
Figure 2 Plain films of the left (a) thumb and (b) elbow obtained at the same time as Fig. 1, demonstrating
heterotopic calcification within the soft tissues.
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phate balance. Surgical resection of remaining
parathyroid tissue is being considered together
with the use of a novel calcimimetic agent to
further suppress parathyroid hormone levels.Discussion
Parathyroid carcinoma is a rare cause of primaryFigure 3 Tc-99m MIBI scintigraphy performed at the
time of the plain films in Fig. 2, demonstrating increased
tracer uptake within the left thumb corresponding to the
known deposit of heterotopic calcification.hyperparathyroidism, occurring in between 0.5 and
5% of all cases.4–6 The clinical course is dominated
by the metabolic effects of hyperparathyroidism,
leading to an often severe hypercalcaemia. Mus-
cular weakness, anorexia, weight loss, increasing
thirst, polyuria, mental depression and psychosis
are frequent presenting symptoms. Presurgical
localization with Tc-99m MIBI scintigraphy is an
increasingly popular technique,1,2 and total-body
imaging has an application in the detection of
metastatic disease.1 The use of Tc-99m MIBI
scintigraphy in the localization of recurrent disease
is also gaining popularity.1,6 Parathyroid carcinoma
is usually slow growing, with a tendency toward
local invasion, but a wide range of malignancy has
been reported.5,6 Metastatic disease in local lymph
nodes, lung and bone are common.6 The only
effective treatment for the primary tumour is
surgical resection.4–6 Only anecdotal reports of
tumour response to chemotherapy or local radio-
therapy are available.
Heterotopic calcification is a metabolic disorder
first reported by Virchow in 1855,7 and is one of the
major types of pathological tissue calcification
described in the literature, characterized by
calcium salt deposition in otherwise normal tissues.
In people with chronic renal insufficiency, various
contributing factors have been identified. The most
important of these is an increased serum calcium–
Figure 4 Plain films of the left (a) thumb and (b) elbow
obtained 20 months following resection of a parathyroid
carcinoma. The known sites of heterotopic calcification
have increased in size and density despite medical
therapy.
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mia, hyperphosphataemia or both. An elevated
parathyroid hormone level has also been postulated
as a contributing factor; however, this remains
contentious.8,9 Local and systemic pH, the presence
of nucleators within the soft tissues, tissue
phosphatase activity, local expression of growth
factors and trauma have been proposed as
additional factors.8–10
Heterotopic calcification has been described in
association with primary and secondary osteolytic
bone tumours, hyperparathyroidism, multiple
myeloma, leukaemia, lymphoma and hypervitami-
nosis D.8 In our case, the combination of chronic
renal failure and marked hyperparathyroidism
secondary to parathyroid carcinoma was implicated
in the formation of the initial site of heterotopic
calcification. However, complete excision of the
parathyroid tumour and biochemical normalization
following surgery failed to prevent the formation of
new areas of calcification. This observation is in
accordance with the literature, which suggests that
parathyroid hormone has a limited role in the
pathogenesis of heterotopic calcification.8,9 In
fact, regression or stabilization of heterotopic
calcification following parathyroidectomy is rarely
observed.8,9
Management of heterotopic calcification, par-
ticularly in persons with chronic renal failure, is
often difficult. The control of serum phosphate
levels is crucial in preventing further calcium salt
deposition.10 Current treatment includes dietary
phosphate restriction, phosphate binders,Figure 5 Axial unenhanced CT of the lower abdomen
obtained 25 months following resection of a parathyroid
carcinoma, showing extensive heterotopic calcification
within the right psoas muscle, posterior abdominal wall
and erector spinae muscles. The involved psoas muscle is
displaced anteriorly.
Figure 6 Tc-99m MIBI scintigraphy performed at the
time of the CT in Fig. 5, demonstrating increased tracer
uptake within the left elbow, which correlates with the
site of heterotopic calcification in Fig. 4(b). Increased
tracer uptake within the left thumb was again noted.
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low-calcium dialysate and surgical excision of the
calcified mass.11,12 Bisphosphonates and steroidal
and non-steroidal anti-inflammatory drugs have
been used for the treatment of severe soft-tissue
calcification in uraemic individuals, but no con-
trolled studies assessing their efficacy are avail-
able.10,11 Overall, the complex pathogenesis of
heterotopic calcification is still poorly understood,
and presently a clinical method to determine the
mineralizing propensity of blood and tissue fluid
does not exist. Effective treatment for this
condition is yet to be established.8,10
In chronic renal failure, the most common site of
calcium deposition is the lung, followed by kidney,
gastric mucosa, skeletal muscle, heart, liver,
thyroid and blood vessels.8 Soft-tissue calcification
is typically composed of microscopic deposits that
render plain films insensitive in their detection.
However, macroscopic collections of heterotopic
calcification on plain film typically appear as large
aggregations of irregular, densely calcified lobules
confined to the soft tissue and correlating clinically
with hard, lobulated masses (which may ulcerate
the skin) attached to the underlying fascia.10
Radionuclide scanning with bone-seeking agents
is a sensitive tool in the detection of diffuse soft-
tissue calcification, with several reports in the
literature describing diffuse uptake of bone agents
in affected organs.8,10 Gallium-67 citrate has also
been found to concentrate in sites of heterotopic
calcification, in the absence of malignancy, inflam-
mation or infection.8 Although radionuclidedetection of soft-tissue calcification is sensitive,
radiographically obvious calcification may not be
apparent on radionuclide bone imaging. This latter
observation has been attributed to a metabolically
inactive or “burnt-out” stage in the soft-tissue
calcification.8
To the best of our knowledge, increased uptake
of Tc-99m MIBI at sites of heterotopic calcification
has not previously been described. Tc-99m MIBI was
initially introduced as a myocardial perfusion
agent. Its use in extracardiac applications is gaining
popularity.1–3,13–15 Presurgical localization of pri-
mary and recurrent parathyroid carcinoma with Tc-
99m MIBI imaging is becoming standard practice in
an growing number of centres.1–3 Its use in imaging
breast and thyroid malignancy, astrocytomas,
benign and malignant bone lesions, tuberculous
lesions and pulmonary lesions in connective tissue
disease13–15 is also receiving increasing interest in
the literature. The exact mechanism of MIBI uptake
by diverse benign and malignant disorders is not
known; however, uptake is probably related to
greater perfusion, cell metabolism, ATP-ase pump
activity and mitochondrial activity.1–3 In the case
described, the raised uptake of MIBI within the left
thumb 9 months following resection of a parathyr-
oid carcinoma was initially suspected to be a site of
metastatic disease, but this was excluded on
subsequent histological analysis.
Pathologically, heterotopic calcification in dia-
lyzed patients consists of fibroadipose tissue with
granular deposits of calcium, which are often
surrounded by a granulomatous reaction.9 The
histopathological specimen from the left thumb in
our case demonstrated such a granulomatous
reaction related to the calcific deposit within the
soft tissues, with no evidence of metastatic
disease, and the same lesion showed increased Tc-
99m MIBI uptake. We propose that tracer uptake
within this granulomatous reaction is responsible
for the image findings. Tc-99m MIBI uptake within
tuberculous granulomas has been documented in
the literature,14 which supports our hypothesis.
Conversely, the lack of tracer uptake in heterotopic
calcification in the left supraclavicular fossa at
initial presentation may have been due to the
absence of granulomatous reaction shown at
histology. This may also explain the lack of Tc-
99m MIBI uptake in the large right abdominal wall
mass that subsequently developed. The develop-
ment of a granulomatous reaction within an
established area of heterotopic calcification may
explain the increased uptake of radiotracer at the
left elbow on the second scan, when it had been
normal on the initial study.
To the best of our knowledge, we describe the
M. Walsh et al.74first report of increased uptake of Tc-99m MIBI at
sites of heterotopic calcification. Awareness of this
observation in patients with a history of parathyroid
carcinoma is important in avoiding an erroneous
diagnosis of metastatic disease, and correlation
with plain film findings is recommended to exclude
a site of heterotopic calcification. Metabolically
active lesions, particularly in patients with chronic
renal failure, may be associated with a granuloma-
tous reaction, which we propose is responsible for
uptake of Tc-99m MIBI. Theoretically, metaboli-
cally active deposits may be more responsive to
biochemical manipulation, such as suppression of
parathyroid hormone levels or the use of bispho-
sphonates. Further research into this area of
functional radionuclide imaging in the assessment
of heterotopic calcification is required. Potentially,
radionuclide imaging may have a role in guiding the
management of this common and often highly
disabling condition.References
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